Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

4basebio Grants New Share Options—What Could Management Incentives Signal About Its Growth Ambitions?

4basebio plc is a Cambridge-based life sciences company quoted on London’s AIM market under the ticker 4BB (4BB.L on data platforms). It develops and manufactures synthetic DNA — and the nanoparticles used to deliver genetic payloads — for the next generation of genetic medicines …

Divya Sood | 23 July 2026

AstraZeneca Edges Higher—Could Its Drug Pipeline Drive the Next Major Breakout?

AstraZeneca PLC is a UK-headquartered biopharmaceutical company and one of the largest constituents of the FTSE 100. It discovers, develops, manufactures and commercialises prescription medicines, with particular strength in oncology alongside meaningful franchises in cardiovascular, renal and metabolic disease, respiratory and immunology, and rare …

Ankur Sharma | 23 July 2026

GSK Shares Retreat—Could Pipeline Concerns Be Creating a Long-Term Opportunity?

GSK plc, with corporate roots reaching back centuries, is a research-based biopharmaceutical company headquartered in the UK and employing roughly 67,000 people. It trades on the London Stock Exchange under the ticker GSK and operates through two broad segments: Commercial Operations and Total R&D.

Ankur Sharma | 23 July 2026

Reckitt Shares Rise as Defensive Stocks Return—Is the Consumer Giant Regaining Investor Trust?

Reckitt Benckiser Group plc is a FTSE 100 consumer-health and hygiene business headquartered in Slough. Its portfolio spans household names such as Dettol, Durex, Nurofen, Strepsils, Vanish, Gaviscon and Finish, alongside the Mead Johnson infant-nutrition brands including Enfamil.

Ankur Sharma | 23 July 2026

Is Futura Medical plc the Next UK Healthcare Stock to Watch After Its Strong Breakout?

Futura Medical plc attracted strong investor attention after its shares gained more than 13% during trading on 22 July 2026.

Ankur Sharma | 23 July 2026

Can Steriwave Transform Ondine Biomedical's Growth Outlook?

Ondine Biomedical Inc. (LSE:OBI) declined3.57% on 22 July 2026, reflecting the considerable volatility that can affect early-stage medical technology companies as investors balance significant commercial opportunities against funding requirements and execution risks.

Divya Sood | 22 July 2026

Why Are Allergy Therapeutics Shares Falling as the Allergy Market Expands?

Allergy Therapeutics PLC shares declined4.62% today (22 July 2026), placing the specialist biotechnology and allergy immunotherapy company among the notable London-listed decliners during the session. The weakness inLSE:AGYcomes as investors continue to evaluate clinical-development progress, commercial execution, funding requirements and the broader risk-reward profile …

Divya Sood | 22 July 2026

Can NIOX Group Plc Sustain Its Position in Healthcare & Diagnostics?

Companies in the healthcare & diagnostics space are typically valued using metrics relevant to their business model and sector peers.

Ishan Mudgal | 22 July 2026

Can MedPal AI Plc Sustain Its Position in Healthcare & Technology?

Companies in the healthcare & technology space are typically valued using metrics relevant to their business model and sector peers.

Ishan Mudgal | 22 July 2026

Can Ondine Biomedical, Inc. Sustain Its Position in Healthcare & Biotech?

Companies in the healthcare & biotech space are typically valued using metrics relevant to their business model and sector peers.

Ishan Mudgal | 22 July 2026
Support

Hi! How can we help you today?

Loading…